Abstract
Background: Stroke is a severe and life-threatening disease, owns high rates of disability and mortality.[1] Stroke and ischemic heart disease, chronic obstructive pulmonary disease are the world’s three main killers.Ischemic strokes account for the vast majority of strokes.[2] Modern medicine has some advantages in treating ischemic stroke, but there are also limitations. Traditional Chinese medicine has thousands of years of experience in treating stroke, but there are few high quality clinical Randomized controlled trial.Methods: This is a multicenter, randomized, double-blind, placebo-controlled trial. 286 patients were randomly divided into test group and Control Group. Both groups received General Western medicine treatment, the test group combined with Chinese medicine treatment, the control group combined with placebo treatment. The duration of treatment was 30 days and the follow-up was 90 days. evaluation indicators include: Modified Rankin Scale, NIH stroke Scale, Glasgow Coma Scale, Barthel Index, Case fatality rate.Laboratory specifications and safety assessments will also be taken into account.Discussion: The aim of this study was to evaluate the safety and efficacy of ZFXNY in the treatment of acute cerebral infarction. Our research will provide a reliable evidence-based medicine basis for the treatment of acute cerebral infarction with traditional Chinese medicine, and provide another option for the treatment of acute cerebral infarction.Trial registration: ChiCTR2100043796, Registered February 28th, 2021.
Clinical Evidence-Based Evaluation of ZFXNY in Treatment of Acute Cerebral Infarction
